Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

By R. Motzer, Thomas E. Hutson, P. Tomczak, M. Michaelson, R. Bukowski, O. Rixe, S. Oudard, S. Négrier, C. Szczylik, Sindy T. Kim and 4 more. New England Journal of Medicine, 2007

5,289 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/94cbe62ac647455cb834b42a03ed01daa6919698

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Adamis
2. N. Ferrara
3. B. Rini
4. Charles Swanton
5. N. Vasudev
6. Andrew R Reynolds
7. G. Wilding
8. Rakesh K. Jain

In Pulmonary and Respiratory Medicine

1. B. Rini
2. Pedro C. Barata
3. Charles Swanton
4. N. Ferrara
5. Rakesh K. Jain

Citations in the corpus

• Treatment of renal cell carcinoma: Current status and future directions (2017, result): “5 to 11 months, and the median OS improved from 23 to 26 months, in favor of the experimental arms.(78,79,82) Both outcomes were shorter with temsirolimus compared with TKIs, which was investigated mainly in the poor-risk population with expected worse parameters.”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “6 mth NS Improved 4 [124][125]”
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (2010, result): “The effects of PFS and RR in the treatment-naive subpopulation observed in this phase III trial are comparable to published data for sunitinib and bevacizumab (with IFN).(8,10,11) When this study was initiated in April 2006, limited access to the multikinase inhibitors sunitinib and sorafenib preclu”
• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (2007, neutral): “Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
• Molecular basis for sunitinib efficacy and future clinical development (2007, background): “cgi?id=606764">gastrointestinal stromal tumours (GIST) that are refractory or intolerant to imatini”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Three vascular endothelial growth factor (VEGF)-targeted agents have demonstrated efficacy in pivotal phase III trials, mostly focused on good and intermediate patients: bevacizumab (combined with IFN), sunitinib and pazopanib [41-43].”
• Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009, result): “These results are compatible with the improved efficacy of VEGFtargeted therapies when compared with immunotherapy in randomized, controlled trials.(9,11,12) Factors that are traditionally included, such as elevated LDH levels and nephrectomy status, were not found informative in this model.”
• Systemic therapy in metastatic renal cell carcinoma (2016, background): “Pazopanib was not inferior to sunitinib in a phase 3 study and sunitinib proved to be superior to IFN-α [16, 18].”
• Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. (2017, result): “6 months and 18%, respectively, were lower than those reported in previous trials that included patients of all risk groups, including favorable risk.(7,8) For example, median PFS per investigator was 10.”